CPIM-MPR study help - Certified in Production and Inventory Management - Master Planning of Resources Updated: 2024 | ||||||||
| CPIM-MPR Real test Questions dumps that really work in CPIM-MPR exam | ||||||||
 |
||||||||
|
||||||||
|
Exam Code: CPIM-MPR Certified in Production and Inventory Management - Master Planning of Resources study help January 2024 by Killexams.com team | ||||||||
CPIM-MPR Certified in Production and Inventory Management - Master Planning of Resources Exam Details for CPIM-MPR Certified in Production and Inventory Management - Master Planning of Resources: Number of Questions: The CPIM-MPR test typically consists of 75 multiple-choice questions. Time Limit: The test has a time limit of 3.5 hours (210 minutes). Course Outline: The CPIM-MPR certification test focuses on assessing the knowledge and skills required for effective master planning of resources in the field of production and inventory management. The course outline covers the following key topics: 1. Demand Management: - Understanding demand forecasting techniques - Demand management process and methodologies - Sales and operations planning (S&OP) - Collaborative demand planning and management 2. Sales and Operations Planning (S&OP): - S&OP principles and processes - Developing an aggregate production plan - Capacity planning and management - S&OP performance measurements and analysis 3. Master Scheduling: - Master scheduling process and objectives - Time fences and order promising - Managing material and capacity availability - MPS (Master Production Schedule) creation and maintenance 4. Material Requirements Planning (MRP): - MRP concepts and calculations - Bill of Materials (BOM) and product structure - Inventory management and control - MRP inputs, outputs, and reports 5. Capacity Requirements Planning (CRP): - Capacity planning and management - Resource requirements and availability - CRP calculations and analysis - Load leveling and capacity utilization 6. Planning for Purchasing and Materials Management: - provider relationship management - Vendor selection and evaluation - Purchasing process and procedures - Inventory management techniques Exam Objectives: The CPIM-MPR test aims to assess the following objectives: 1. Understanding of demand management principles and techniques. 2. Proficiency in sales and operations planning (S&OP) and aggregate production planning. 3. Knowledge of master scheduling techniques and master production schedule (MPS) management. 4. Competence in material requirements planning (MRP) and inventory management. 5. Familiarity with capacity requirements planning (CRP) and capacity management. 6. Understanding of purchasing and materials management principles and practices. Exam Syllabus: The CPIM-MPR test covers the following syllabus: 1. Demand Management - Demand forecasting techniques - Demand management process and methodologies - Sales and operations planning (S&OP) - Collaborative demand planning and management 2. Sales and Operations Planning (S&OP) - S&OP principles and processes - Developing an aggregate production plan - Capacity planning and management - S&OP performance measurements and analysis 3. Master Scheduling - Master scheduling process and objectives - Time fences and order promising - Managing material and capacity availability - MPS (Master Production Schedule) creation and maintenance 4. Material Requirements Planning (MRP) - MRP concepts and calculations - Bill of Materials (BOM) and product structure - Inventory management and control - MRP inputs, outputs, and reports 5. Capacity Requirements Planning (CRP) - Capacity planning and management - Resource requirements and availability - CRP calculations and analysis - Load leveling and capacity utilization 6. Planning for Purchasing and Materials Management - provider relationship management - Vendor selection and evaluation - Purchasing process and procedures - Inventory management techniques | ||||||||
| Certified in Production and Inventory Management - Master Planning of Resources APICS Production study help | ||||||||
Other APICS examsCSCP APICS Certified Supply Chain ProfessionalCPIM-BSP CPIM - Basics of Supply Chain Management CPIM-MPR Certified in Production and Inventory Management - Master Planning of Resources CLTD Certification in Logistics, Transportation and Distribution | ||||||||
| killexams.com CPIM-MPR test PDF consists of Complete Pool of Braindumps with Dumps checked and confirmed along with references and explanations (where relevant). Our target to gather the Braindumps isn't always only to pass the test at the first attempt but Really Boost Your Knowledge about the CPIM-MPR test topics. | ||||||||
| APICS CPIM-MPR Certified in Production and Inventory Management - Master Planning of Resources https://killexams.com/pass4sure/exam-detail/CPIM-MPR Question: 96 When quantitative data are being evaluated, a very small bias in a forecast can best be explained by which of the following statements? A. Positive forecast errors approximately offset negative forecast errors. B. The absolute values of all forecast errors were approximately equal. C. The variability of forecast data was skewed. D. A very small alpha factor was used. Answer: A Question: 97 Which of the following actions would most likely lead to an achievable master production schedule? A. Minimizing changes in periods before the demand time fence B. Keeping safety stock for key subassemblies C. Limiting changes in periods after the planning time fence D. Committing to customer requested shipment dates Answer: A Question: 98 Which of the following considerations is most important when selecting forecasting software? A. Cost of data storage B. Ability to forecast over multiple planning horizons C. Ability to forecast capacity requirements D. Computational speed Answer: B Question: 99 Identification of performance problems in providing a high line-item service ratio provides an opportunity to: A. address imbalances in the customer order mix. B. Boost order-promising information. C. redesign sales and marketing incentives. D. reduce customer-demanded delivery time. Answer: B Question: 100 In an assemble-to-order environment, which of the following indicators is most appropriate for measuring the effectiveness of the master scheduling process? A. Customer order fill rate B. Number of stock outs C. Capacity utilization D. Aggregate inventory Answer: A Question: 101 Which of the following issues is most likely to lead to the use of a short-term, rather than long-term, forecasting process? A. How to respond to a competitor's test marketing of a new product B. How to configure the supply chain to support a new market segment C. Whether to outsource a capital-intensive subassembly process D. Whether to take a price-leadership or a product-differentiation posture Answer: A Question: 102 Distribution requirements planning would most directly interface with: A. capacity requirements planning. B. master planning. C. material requirements planning. D. warehouse facility planning. Answer: B Question: 103 Which of the following functional objectives of a distribution system is most consistent with lower inventories? A. Low warehousing costs B. Low transportation costs C. Fast deliveries D. High customer service Answer: A Question: 104 Using a trial and error approach is most effective in which of the following production planning strategies? A. Level B. Constant C. Chase D. Mixed Answer: D Question: 105 An effective implementation of the sales and operations planning (S&OP) processes would typically result in the firm's ability to: A. increase its market share. B. position products in the marketplace. C. reduce budget variances. D. respond to new opportunities. Answer: D For More exams visit https://killexams.com/vendors-exam-list Kill your test at First Attempt....Guaranteed! | ||||||||
|
In a relaxed environment, these student-led, question and answer sessions provide you with encouragement and support while permitting you to come and go as needed. Remember, all ASC services are free! Please check with individual departments for up-to-date drop-in group help/study session offerings. Additional information will be available shortly after the start of each semester. Accounting Help Sessions CHEMISTRY 221 CSCI 112, 125, 235, 245, 255 Sundays, 6–8 p.m. Mondays–Thurdays, 7–9 p.m. VanderWerf 115 Led by computer science students Help Session Tuesdays, 11–11:50 a.m. Van Zoeren 245 Led by Professor Susan Cherup Engineering 100 Help Sessions Engineering 210 Help Sessions Engineering 220 Help Sessions Thursdays, 12:30–1:30 p.m. Japanese Assistance Japanese 101 Drill Sessions Friday, 4–5 p.m. Japanese 201 Drill Sessions Drop-in help for students enrolled in quantitative courses Mondays–Thursdays, 7:30–9:15 p.m. Schaap 1118 Led by upper-level math students *For students in a math or quantitative course Physics 105 and 121 Help Sessions Thursdays, 6:30–8:30 p.m. Watch CBS News
Be the first to know Get browser notifications for breaking news, live events, and exclusive reporting. The latest weight loss craze could also help people control their drinking. Semaglutide treatments such as Ozempic and Wegovy have been shown to reduce the symptoms of alcohol use disorder (AUD), according to a study published in The Journal of Clinical Psychiatry on Nov. 27. The collaborative study from The University of Oklahoma (OU) and Oklahoma State University (OSU) found a “significant and noteworthy decrease” in the Alcohol Use Disorders Identification Test (AUDIT) scores of six patients who were receiving semaglutide treatment for weight loss. Lead study author Dr. Jesse Richards, director of obesity medicine and assistant professor of medicine at the OU-TU School of Community Medicine, said the study was inspired by his conversation with Dr. Kyle Simmons, professor of pharmacology and physiology at the OSU Center for Health Sciences. “I had been hearing from a significant number of patients that their alcohol intake was spontaneously decreasing while [they were] on the medication,” Richards told Fox News Digital. As a bariatric surgery clinic employee, Richards noted that it’s standard to screen patients for alcohol use. At the clinic, a number of patients tested positive for alcohol consumption, sometimes in concerning amounts. Later, while on semaglutide medication, they reported reduced alcohol intake. One of Richards’ patients — who previously drank large amounts of alcohol — shared a new inability to drink more than two cans of beer now because it “just doesn’t sound good.” This response piqued Richards’ interest in learning more about patients’ aversion to alcohol, which directly correlated to his research. Research has shown that this effect is “mediated through adjustments in the reward pathway in the brain,” he said. “The GLP-1s are actually modifying dopamine, decreasing the craving and decreasing the motivation to acquire things in that compulsive intake category.” The most surprising takeaway from the study, Richards said, was that the same significant treatment response was seen even at very low doses. “We found that even patients on the lowest dose of semaglutide — a quarter milligram — had a quite significant and relatively … quick onset reduction in alcohol intake,” he said. Of the six patients studied, all but one were on low doses — from a quarter to a half milligram. “And that’s very encouraging because we know that the lower doses of these medications are tolerated much better,” said Richards. While the results seem promising, the doctor said he does not recommend that patients use semaglutide treatments for alcohol use disorder at this time, due to supply and safety issues. “If patients have [obesity and diabetes] indications for the medication and they also struggle with alcohol intake … having them on this treatment may potentially be beneficial,” Richards said. “But because there has been a global medication shortage, and because we don’t have prospective trials and don’t know what the specific safety is versus the well-established safety data in obesity and diabetes, [I] would not recommend it just for patients who have AUD.” There are three FDA-approved drugs available for alcoholic use disorder that are currently underused, the doctor noted. Given that five million people in the U.S. are currently taking semaglutide medications, if it is proven that those drugs have a significant effect on alcohol use disorder, “by default, they are going to become the most widely used drug to Boost these symptoms — just by virtue of the fact that so many people are on them for diabetes or obesity,” Richards noted. He confirmed that additional research is underway with two ongoing trials. “Since we were able to show clinically meaningful reductions in alcohol intake and AUD symptomatology in a real-world setting, that bodes very well for these types of medications,” he said. Looking ahead, Richard said there is a need for higher-quality evidence of the medication’s impact on AUD compared to placebo drugs or environmental factors. Even though it’s unclear whether GLP-1 producers will market the medication to AUD patients in the future, Richards said this could become an “established medical practice once the safety and efficacy has been determined.” For patients who struggle with AUD, Richards recommended they talk to their health care providers about available treatment. He also alerted patients that if they experience a reduced appetite and usually consume “a bunch of calories” in alcohol, it may be necessary to look into a more balanced diet. Avantika Waring, 9amHealth’s chief medical officer and a trained physician and endocrinologist in San Francisco, applauded the OU and OSU study findings for further supporting what clinicians “are already seeing in practice,” she told Fox News Digital. “GLP-1 medications have a lot of effects that we are still learning about, and the ability to decrease cravings and the reward signals related to alcohol use are just some of the benefits,” she said. “It’s an important starting point for further clinical trials,” she added. Waring also warned that GLP-1 medications should not be used to treat AUD specifically, as they can cause side effects such as nausea and changes in appetite. “People struggling with alcohol use disorder should consult with their physicians before starting GLP-1 medications to make sure that they can stay hydrated and safe on therapy,” she said. Waring noted that if ongoing clinical trials find semaglutide treatments to be effective for AUD, the medical community will “have another tool to help people living with alcohol addiction and we’ll see expanded use of these already popular drugs.” Fox News Digital reached out to Novo Nordisk for comment on the potential link between semaglutide medications and alcohol use disorder.
Getty
They say that there's no sense in crying over spilled milk. But what do they know? Crying can get you another glass of milk if you do it loud enough. Plus, crying may serve a real physiologic purpose, according to a study published recently in Emotion, meaning the journal and not in an Emo-kind of way. For the study, three researchers from the University of Queensland (Leah S. Sharman, Genevieve A. Dingle, and Eric J. Vanman) and one from Tilberg University (Ad J. J. M. Vingerhoets) recruited 197 female undergraduate students. They said that they choose all women rather than including men because pilot testing of sad videos had revealed that more women than men cried or at least more women revealed that they were crying. This did not account for the men who cried inside or used some bro-language or high fives to hide the crying. The research team then showed each of the study participants either a video that are supposed to make them feel sad (sad videos) or a video that was not supposed to elicit any emotion (neutral videos) like something from a documentary or a ted talk. Each video lasted for close to 18 minutes. After the video, the researchers noted whether or not each participant had cried while watching the video. Ultimately, 65 participants watched the neutral video, 71 watched the sad video and cried during it, and 61 watched the sad video and did not cry. Presumably, no one cried during the neutral video. But then again, actor Bryce Dallas Howard was able to cry when Conan O'Brien talked about Home Depot in this Conan clip: Then, each participant underwent a Cold Pressor Stress Test (CPT), which involved placing the participant's left hand, up to the wrist, in cold 0° to 5°C water. Unless you are the Iceman or Killer Frost, this is supposed to be painful. The research team measured how long each participant could stay in this position until pulling her hand out of the water. During the study, the research team continuously measured each participant's heart rate and respiratory rate and periodically measured cortisol levels from saliva samples. Cortisol is a stress-hormone that's produced by the body. Also, at four points during the study, participants answered questions from the Positive and Negative Affect Scale short form (PANAS). These questions asked the degree to which the participant was experiencing ten different emotions and to rank each on a five-point scale that ranged from a one (very slightly or not at all) to a five (extremely). When it came to cortisol levels and how long the participants could keep their hands submerged in the cold water, the study ended up finding not much difference between the neutral video watchers, the sad video non-criers, and the sad video criers. So if you are about to dunk yourself in cold water or take a cold shower, it may not help to cry first. But here's a difference that the study found. Are you ready? Take a deep breath. The difference was breathing rates. While watching the videos, the non-criers tended to have elevations in their breathing rates, whereas, by contrast, the criers tended to maintain their initial breathing rates. In other words, tearing up could have helped participants better control their breathing rates. This provides further evidence that crying may help you better regulate arousal, serving as an emotional release. Another interesting finding was that right before crying, participants tended to experience decreases in their heart rates, seemingly in anticipation of the crying. Once the crying began, their heart rates then tended to creep back up but not above where their heart rates had been before everything began. This may be further evidence that crying has a beneficial regulatory effect on your physiology. So perhaps next time you start crying you can tell people that you are regulating your physiology. You've probably heard of people saying that they had a good cry and feel better after they've let the tears flow. It can be important to find reasonable ways to periodically release your emotions. Otherwise, you may end up bottling everything up like a hot air balloon that can explode when you least expect it. Moreover, crying can be a way of communicating. It's really the only way that babies can express their needs before they learn how to say things like "why you throwing shade on me," or "I'm not Gucci." Crying can help communicate to others that you need more sympathy, comfort, or help. Of course, this can be misused. You don't want to cry every time your order at a restaurant doesn't come out right. And of course, there is the whole concept of crocodile tears: people crying to get something when they don't really mean it. Crying can also be a way of communicating with yourself. Even when you cry alone, you may be telling yourself about your own state because, like many people, you could be terrible at practicing your own emotions and situation. Tears could be your body's way of saying, "hey, take a break," or "something's not right," or "take care of yourself." Tearing up can then be a way of your body literally crying out to you. Your body is a complex system. Crying can be complex. Your tears can flow when you are very sad, very angry, or even very happy. Better understanding what causes us to cry and what happens as a result could help us better handle our emotions and stress. A new study suggests getting that cute dog in one's more mature years might be a good idea after all. Researchers from the Sun Yat-sen University in Guangzhou, China, found that pet ownership can be associated with slower rates of developing dementia. The study, published on Tuesday in JAMA Network Open, determined that owning a pet made a difference in verbal memory and fluency among adults who lived alone. NEW STUDY SHOWS THE EFFECT OWNING PETS HAS ON OWNERS' BRAINS The study's author, professor Ciyong Lu, said in the study that slower rates of declining verbal memory and fluency were seen in those who lived alone — but not in those who lived with others. "Pet ownership offset the associations between living alone and declining rates [of] verbal memory and verbal fluency," he said. Researchers found that owning a pet helps those with dementia. (iStock) The research involved more than 7,900 participants over the age of 50, with roughly 35% of them owning pets and 27% of them living alone. In the study, Lu said that those living alone with a pet showed slower rates of developing signs of dementia. DOG OWNER GOOD NEWS: PETTING YOUR DOG MAY LEAD TO STRONGER MEMORY AND BETTER PROBLEM SOLVING SKILLS "These findings suggest that pet ownership may be associated with slower cognitive decline among older adults living alone," he said. "Contrary to living alone," the authors also wrote, "pet ownership (for example, raising dogs and cats) is related to reduced loneliness, an important risk factor for dementia and cognitive decline." A new study found that owning a pet could be beneficial for people with signs of dementia who live alone. (iStock) Lu said that clinical trials will be necessary in order to confirm the study's findings. Currently, more than 55 million people worldwide have dementia — with nearly 10 million new cases each year, according to the World Health Organization (WHO). EATING ONE POPULAR FRUIT COULD HELP REDUCE YOUR CHANCES OF DEVELOPING DEMENTIA, STUDY FINDS Alzheimer's disease is the most common form of dementia, which is currently the 7th leading cause of death, the WHO also notes. Early symptoms of dementia include forgetfulness, being confused, losing track of time, misjudging distances, feeling anxious, experiencing personality changes, engaging in inappropriate behavior and more. (iStock) Early symptoms of dementia include forgetfulness, being confused, losing track of time, misjudging distances, feeling anxious, personality changes, inappropriate behavior and more. CLICK HERE TO GET THE FOX NEWS APP There is currently no cure for dementia or for someone developing signs of dementia, but the WHO suggests that staying active and continuing to stimulate the brain may help. CLICK HERE TO SIGN UP FOR OUR LIFESTYLE NEWSLETTER Fox News Digital reached out to Lu for further comment. For more Lifestyle articles, visit www.foxnews.com/lifestyle. The latest weight loss craze could also help people control their drinking. Semaglutide treatments such as Ozempic and Wegovy have been shown to reduce the symptoms of alcohol use disorder (AUD), according to a study published in The Journal of Clinical Psychiatry on Nov. 27. The collaborative study from The University of Oklahoma (OU) and Oklahoma State University (OSU) found a "significant and noteworthy decrease" in the Alcohol Use Disorders Identification Test (AUDIT) scores of six patients who were receiving semaglutide treatment for weight loss. Lead study author Dr. Jesse Richards, director of obesity medicine and assistant professor of medicine at the OU-TU School of Community Medicine, said the study was inspired by his conversation with Dr. Kyle Simmons, professor of pharmacology and physiology at the OSU Center for Health Sciences. "I had been hearing from a significant number of patients that their alcohol intake was spontaneously decreasing while [they were] on the medication," Richards told Fox News Digital. Semaglutide treatments such as Ozempic and Wegovy have been shown to reduce symptoms of alcohol use disorder, according to a new study published in The Journal of Clinical Psychiatry. (iStock; SEBASTIEN BOZON/AFP via Getty Images) As a bariatric surgery clinic employee, Richards noted that it’s standard to screen patients for alcohol use. OZEMPIC-WEGOVY PILL MAY BE ON THE WAY: TRIAL SHOWS PROMISING RESULTS FOR NEW WEIGHT LOSS TABLET At the clinic, a number of patients tested positive for alcohol consumption, sometimes in concerning amounts. Later, while on semaglutide medication, they reported reduced alcohol intake. Dr. Jesse Richards is director of obesity medicine at OU Health at the Hardesty Center for Clinical Research and Neuroscience in Tulsa, Oklahoma. "I had been hearing from a significant number of patients that their alcohol intake was spontaneously decreasing while on the medication," he told Fox News Digital. (OSU Center for Health Sciences) One of Richards’ patients — who previously drank large amounts of alcohol — shared a new inability to drink more than two cans of beer now because it "just doesn’t sound good." This response piqued Richards' interest in learning more about patients' aversion to alcohol, which directly correlated to his research.
Research has shown that this effect is "mediated through adjustments in the reward pathway in the brain," he said. "The GLP-1s are actually modifying dopamine, decreasing the craving and decreasing the motivation to acquire things in that compulsive intake category." "Reducing liquid sugar and liquid caloric intake is strongly associated with effective weight loss," an expert told Fox News Digital. (iStock) The most surprising takeaway from the study, Richards said, was that the same significant treatment response was seen even at very low doses. "We found that even patients on the lowest dose of semaglutide — a quarter milligram — had a quite significant and relatively … quick onset reduction in alcohol intake," he said. Of the six patients studied, all but one were on low doses — from a quarter to a half milligram. OZEMPIC, WEGOVY MAY BE LINKED TO STOMACH PARALYSIS AND OTHER DIGESTIVE ISSUES IN LARGE-SCALE STUDY "And that's very encouraging because we know that the lower doses of these medications are tolerated much better," said Richards. While the results seem promising, the doctor said he does not recommend that patients use semaglutide treatments for alcohol use disorder at this time, due to supply and safety issues. Wegovy is an injectable prescription weight loss medicine that has helped people address obesity. (Michael Siluk/UCG/Universal Images Group via Getty Images) "If patients have [obesity and diabetes] indications for the medication and they also struggle with alcohol intake … having them on this treatment may potentially be beneficial," Richards said. "But because there has been a global medication shortage, and because we don't have prospective trials and don't know what the specific safety is versus the well-established safety data in obesity and diabetes, [I] would not recommend it just for patients who have AUD." OZEMPIC, WEGOVY AND PREGNANCY RISK: WHAT YOU NEED TO KNOW ABOUT THE ISSUE There are three FDA-approved drugs available for alcoholic use disorder that are currently underused, the doctor noted. "Unfortunately, at this point, only about 2% of people with AUD are on an approved treatment," he said. GLP-1 treatments do not have a warning against consuming alcohol while taking the drugs, an expert pointed out. (iStock) Given that five million people in the U.S. are currently taking semaglutide medications, if it is proven that those drugs have a significant effect on alcohol use disorder, "by default, they are going to become the most widely used drug to Boost these symptoms — just by virtue of the fact that so many people are on them for diabetes or obesity," Richards noted. OZEMPIC, WEGOVY AND ALL THOSE CRAZY, VIVID DREAMS: IS THERE A CONNECTION? He confirmed that additional research is underway with two ongoing trials. "Since we were able to show clinically meaningful reductions in alcohol intake and AUD symptomatology in a real-world setting, that bodes very well for these types of medications," he said. Looking ahead, Richard said there is a need for higher-quality evidence of the medication's impact on AUD compared to placebo drugs or environmental factors. Health care providers wrote more than nine million prescriptions for Ozempic and similar drugs in the last quarter of 2022, data shows. (SEBASTIEN BOZON/AFP via Getty Images) Even though it’s unclear whether GLP-1 producers will market the medication to AUD patients in the future, Richards said this could become an "established medical practice once the safety and efficacy has been determined." For patients who struggle with AUD, Richards recommended they talk to their health care providers about available treatment. CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER He also alerted patients that if they experience a reduced appetite and usually consume "a bunch of calories" in alcohol, it may be necessary to look into a more balanced diet. Avantika Waring, 9amHealth's chief medical officer and a trained physician and endocrinologist in San Francisco, applauded the OU and OSU study findings for further supporting what clinicians "are already seeing in practice," she told Fox News Digital.
"GLP-1 medications have a lot of effects that we are still learning about, and the ability to decrease cravings and the reward signals related to alcohol use are just some of the benefits," she said. "It’s an important starting point for further clinical trials," she added. Waring also warned that GLP-1 medications should not be used to treat AUD specifically, as they can cause side effects such as nausea and changes in appetite. Patients' aversion to alcohol is part of balancing the "side effects with the benefit" of the medication, said the lead study author. (iStock) "People struggling with alcohol use disorder should consult with their physicians before starting GLP-1 medications to make sure that they can stay hydrated and safe on therapy," she said. CLICK HERE TO GET THE FOX NEWS APP Waring noted that if ongoing clinical trials find semaglutide treatments to be effective for AUD, the medical community will "have another tool to help people living with alcohol addiction and we’ll see expanded use of these already popular drugs." Fox News Digital reached out to Novo Nordisk for comment on the potential link between semaglutide medications and alcohol use disorder. Gradual process. Beautiful mature woman touching sweater and having hot flash gettyAround 1.3 million women experience menopause in the United States each year. Although menopause begins between 51 and 52 years old, about 5% of women experience early menopause between 40 and 45 years old, while 1% experience premature menopause before the age of 40. The most significant symptoms of menopause are hot flashes, sleep problems, low libido, and mood changes. There are different treatments to manage menopause, including hormonal and non-hormonal therapies. Furthermore, lifestyle changes, such as eating well, exercising, and looking after mental well-being, can help with symptoms during menopause. But as cannabis has become legally available due to its regulation in many US states for both medical and recreational purposes, some women are consuming it to successfully manage menopause, as a latest study has recently shown. Researchers from McLean Hospital Imaging Center, Belmont, MA, and Department of Psychiatry, and Harvard Medical School, Boston, MA, conducted a survey study recently published in Menopause: The Journal of The North America Menopause Society to find out how the use of cannabis affects women with menopause-related symptoms. Results suggest that numerous women currently use cannabis as an adjunctive treatment for menopause-related symptoms, especially to treat sleep disorders, mood and anxiety, and low libido. According to the study, cannabinoid treatment can help manage menopause symptoms as the endocannabinoid system involves various physiological and psychological processes, such as regulating body temperature, mood, anxiety, and sleep. In particular, the authors of this study think that cannabis compounds could interact with anandamide, a chemical compound produced by the ovaries whose production drops during menopause. Anandamide is part of the endocannabinoid system, which regulates the human body's emotional, sleeping, and temperature functions and influences the female reproductive system. Therefore, the interaction between cannabis compounds and anandamide, which levels are thought to be correlated with estrogen levels, could mitigate the trigger of the symptoms during the menopause transition. The authors of the survey study recruited perimenopausal and postmenopausal participants on social media platforms between March 2020 and April 2021. Perimenopause is when the body makes the natural transition to menopause. Instead, postmenopause refers to when an individual hasn't experienced a period for over a year. Participants completed self-report questionnaires reporting their medical conditions, medications, menopause-related symptoms, cannabis use in general, and cannabis use for menopause-related symptoms, and included their history of cannabis use. Overall, the survey included 258 participants. Most participants were primarily White, non-Hispanic, middle-aged women who reported an annual income reflecting middle-class status or above, completed an undergraduate degree or higher, were married or in a relationship, and were employed at least part-time. Most participants reported at least one-lifetime use of cannabis (92.0%). In comparison, 83.5% of participants reported they use cannabis at least once a month, and 86.1% reported more frequent cannabis use. While 51.5% of participants reported using cannabis for both medical and recreational use, 30.8% reported using cannabis for recreational use only, and 17.7% for medical purposes only. The most used methods to consume cannabis among this study's participants were smoking, edibles, and vaping oil. Of those who reported at least one-lifetime use of cannabis, 78.7% reported using it to treat menopause symptoms, in particular sleep disorder (67.4%), anxiety (46.1%), and low libido (30.4%). Although these findings show that cannabis may help alleviate menopause-related symptoms, the study has several limitations to consider. As most participants are White, the result from this study may not be generalized as evidence suggests that race and ethnicity significantly impact menopause symptom presentation. For instance, Black individuals have a higher risk for vasomotor symptoms, and Hispanic individuals have a greater risk for mood changes than White individuals. Also, the authors suggest that "the findings from this survey study rely exclusively on self-report and may have been impacted by self-report bias and inaccurate recall." At last, this survey study doesn't discuss profiles and dosage of cannabis, which can significantly impact the efficacy of treating menopause and the safety of the individuals. 
usatoday.com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use. Unfortunately, your browser is not supported. Please get one of these browsers for the best experience on usatoday.com | ||||||||
CPIM-MPR action | CPIM-MPR course outline | CPIM-MPR test Questions | CPIM-MPR download | CPIM-MPR action | CPIM-MPR test Questions | CPIM-MPR action | CPIM-MPR study help | CPIM-MPR test Questions | CPIM-MPR PDF Download | | ||||||||
Killexams test Simulator Killexams Questions and Answers Killexams Exams List Search Exams |
